News and Trends 17 Mar 2023 How cancer cells repair DNA damage from radiotherapy A team of scientists led by Kei-ichi Takata from the Center for Genomic Integrity (CGI) within the Institute for Basic Science (IBS) in South Korea, has discovered a new type of DNA repair mechanism that cancer cells use to recover from next-generation cancer radiation therapy. Ionizing radiation (IR) therapy is frequently used in the treatment […] March 17, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2023 Inspire Biotherapeutics launches to target lung diseases through gene therapy Inspire Biotherapeutics Inc., an emerging Canadian biotech company with a mission to create gene therapies for monogenic and acquired diseases of the lung, is set to move its novel lung tropic AAV gene therapy into clinical validation. The AAVenger platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types […] March 16, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2023 Mediar Therapeutics boosts fibrosis portfolio with $105M financing Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, has announced a $105 million financing. This includes a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol […] March 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2023 Nanite receives funding to deliver genetic therapies to the lungs Nanite Inc. has announced an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technologies for the lung. This builds on the $6 million seed financing recently announced by the company. One of the most significant challenges in developing new therapies for patients with cystic fibrosis is effective drug […] March 15, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2023 Cambrian Bio to boost aging pipeline with Amplifier Therapeutics launch Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, has launched its new pipeline company, Amplifier Therapeutics. The organization will develop ATX-304, a pan-AMPK (AMP-activated protein kinase) activator. Amplifier has also acquired Betagenon AB, a Swedish biopharmaceutical company, which has discovered novel AMPK activators. It will continue its work […] March 15, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Mar 2023 10 immunotherapy companies making waves in 2023 Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological therapy in 1891. Soon enough, the transformative power of cancer vaccines were observed where tumor-specific antigens triggered antitumor immune responses. Along with these technological advancements, […] March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Mar 2023 7 biotechs in Hungary you should know about Hungary is famous for many things: thermal baths, goulash, beautiful architecture and, of course, the Rubik’s cube. But, what is going on in the country’s biotech industry? The answer is: more than you might think. Did you know that Hungary could be considered the birthplace of European biotechnology? A Hungarian agricultural engineer was the first […] March 15, 2023 - 9 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Expert Advice 14 Mar 2023 5 reasons why collaboration is important in research In the life sciences industry, collaboration is paramount in the field of research, to help move ideas and programs forward through the various stages. Here, experts explain the importance of research collaboration for biotechs. Collaboration in research is critical for the long-term success of biotechs, and going it alone is rarely a feasible option, particularly […] March 14, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen is a global biotechnology company that discovers, develops and commercializes cancer medicines. The boards of directors of both companies have unanimously approved the transaction. “Pfizer is deploying its financial resources to […] March 14, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 Astellas menopause study meets endpoints but leukemia drug disappoints There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor […] March 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 How the microbiome can predict cancer immunotherapy success A new study shows antibiotic treatment prior to CAR-T cell therapy is connected to unfavorable treatment outcomes. An international team headed by Eran Elinav of the Cancer & Microbiome Division of the German Cancer Research Center (DKFZ), and led by Christoph Stein-Thoeringer, professor of Clinical Infectiology and Translational Microbiome Research at the Medical Faculty of […] March 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 Calliditas shares rise as phase 3 endpoints met in kidney disease trial Swedish company Calliditas Therapeutics AB has announced positive topline results from the global, randomized, double-blind, placebo-controlled phase 3 clinical trial investigating the effect of Nefecon (TARPEYO/Kinpeygo (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). Calliditas share prices rose 30% in the aftermath of the announcement. IgAN, or Berger’s disease, is […] March 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email